Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA-BCL6-1: LY4584180 in Previously Treated Hematologic Malignancies
NCT07226843Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of LY4584180 in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), follicular lymphoma (FL) and 1 more (4 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Dose-Limiting Toxicities at Day 28, Serious Adverse Events at 3 years and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
LY4584180
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07226843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226843.